R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis  by Ye, Dan et al.
Cancer Cell
PreviewsR-2-Hydroxyglutarate as the Key Effector
of IDHMutations Promoting OncogenesisDan Ye,1 Shenghong Ma,1 Yue Xiong,1,2 and Kun-Liang Guan1,3,*
1Key Laboratory of Molecular Medicine of Ministry of Education and Institutes of Biomedical Sciences, Shanghai Medical College,
College of Life Science, Fudan University, Shanghai 200032, China
2Lineberger Comprehensive Cancer Center, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599, USA
3Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
*Correspondence: kuguan@ucsd.edu
http://dx.doi.org/10.1016/j.ccr.2013.03.005
The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal
catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG). A recent study
now shows that R-2-HG can reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential
of targeting mutant IDH1 and IDH2.Mutations in metabolic enzymes (isoci-
trate dehydrogenase 1 and 2 [IDH1/2],
fumarate hydratase [FH], and succinate
dehydrogenase [SDH]) have been found
in human cancer (Oermann et al., 2012).
IDH1 and IDH2 are the most frequently
mutated metabolic genes identified in
human cancers, commonly observed in
secondary glioblastomas, cytogenetically
normal acute myeloid leukemias (AML),
cartilaginous tumors, and intrahepatic
cholangiocarcinomas. The IDH enzymes
normally catalyze the oxidative decarbox-
ylation of isocitrate to produce a-ketoglu-
tarate (a-KG) and NADPH. A remarkable
feature shared by cancer-associated
IDH mutations is the loss of IDH’s normal
catalytic activity to produce a-KG and the
gain of a neomorphic function to produce
the R-enantiomer of 2-hydroxylglutarate
(R-2-HG) (Dang et al., 2009). IDH1/2
mutant tumor cells are thus expected to
have a reduced a-KG level and an in-
creased R-2-HG level, which, under
normal physiological conditions, is pre-
sent at extremely low concentrations, if
any, but can accumulate to high levels
(millimolars) in tumors. A key issue
in studying IDH1/2 mutation-induced
tumorigenesis is the pathophysiological
function of R-2-HG.
2-HG is structurally similar to a-KG with
the exception of the oxidation state on the
carbon C-2 position, whereby a hydroxyl
group in 2-HG replaces a ketone group
in a-KG. This structural similarity suggests
the possibility that 2-HG may act as a
competitive inhibitor of a-KG by antago-
nizing the function of a-KG-dependent
enzymes such as the a-KG-dependent274 Cancer Cell 23, March 18, 2013 ª2013 Edioxygenases (Loenarz and Schofield,
2008). These enzymes are involved in
a wide range of cellular regulations from
demethylation of DNA and histone
to protein hydroxylation, including the
hydroxylation and degradation of hypoxia
inducible factor 1a (HIF-1a). Indeed,
recent studies show that 2-HG can inhibit
the activity of multiple a-KG-dependent
dioxygenases (Chowdhury et al., 2011;
Xu et al., 2011), among them, the JmjC
domain-containing histone demethylases
(KDMs) and the ten-eleven translocation
(TET) family of DNA hydroxylases, which
is a tumor suppressor and critically impor-
tant for the demethylation of 5-methylcy-
tosine (5mC) in DNA. 2-HG binds to the
a-KG binding pocket in dioxygenases,
thereby acting as a competitive inhibitor
of a-KG (Xu et al., 2011). The inhibition
of TET enzymes by 2-HG is particularly
noteworthy because TET2 is also fre-
quently mutated in AML, in which IDH1/2
mutations are common. Moreover, muta-
tions of IDH1/2 and TET2 genes are mutu-
ally exclusive in AML (Figueroa et al.,
2010), indicating that they may act in the
same pathway. Furthermore, AML with
either IDH1/2 or TET2 mutations display
similar genomic DNA methylation and
gene expression profiles, indicating that
TET2 is a pathologically relevant target
of 2-HG. Therefore, altered epigenetic
modification is currently considered a
major mechanism underlying the tumori-
genesis associated with IDH1/2 muta-
tions (Oermann et al., 2012) (Figure 1).
Despite correlative evidence for the
role of 2-HG in mediating the oncogenic
effects of IDH1/2 mutations, 2-HG haslsevier Inc.not been formally proven to induce onco-
genic transformation. Losman et al. (2013)
now provide compelling evidence that
2-HG is indeed an oncometabolite
capable of stimulating proliferation and
suppressing differentiation, two proper-
ties obligatory for tumorigenesis in a
cell culture leukemia model. The TF-1
human erythroleukemia cell line requires
the cytokine granulocyte-macrophage
colony-stimulating factor (GM-CSF) for
proliferation and erythropoietin (EPO) for
differentiation. Using this cell line model,
the authors found that expression of the
cancer-associated IDH1 R132H mutant,
but not wild-type IDH1, promoted TF-1
cell proliferation even in the absence of
GM-CSF and inhibited differentiation in
response to EPO. Moreover, expression
of an IDH1 R132H mutant unable to
produce R-2-HG did not induce transfor-
mation of TF-1 cells. These data suggest
that R-2-HG functions as an oncometa-
bolite by promoting cytokine-indepen-
dent growth and blocking EPO-induced
differentiation.
Direct evidence for an oncogenic func-
tion of R-2-HG was obtained by treating
TF-1 cells with a cell permeable R-2-HG
analog (Losman et al., 2013). TF-1 cells
passaged in the presence of the cell
permeable R-2-HG gained cytokine-
independent growth and no longer differ-
entiated in response to EPO, phenotypes
similar to those caused by the mutant
IDH1 R132H expression. These observa-
tions show that R-2-HG is the key factor
that mediates the oncogenic function of
mutant IDH1 in TF-1 cells. It took those
cells several passages to acquire both
Figure 1. A Proposed Model for R-2-HG in Tumorigenesis
R-2-HG produced by the mutant IDH1/2 promotes tumorigenesis by inhibiting 5mC hydroxylase (TET2) and lysine demethylases (KDM), leading to the deme-
thylation of DNA and histone, respectively. The epigenetic alterations associated with IDH1/2 mutations result in changes of gene expression and tumorigenesis.
These processes can be recapitulated by R-2-HG, demonstrating R-2-HG as a true oncometabolite. R-2-HG does not inhibit, but rather stimulates EglN1, which
promotes HIF-1a degradation by hydroxylation. HIF-1a might suppress leukemogenesis, but this may not apply to other cancer types with IDH1/2 mutations.
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to differentiate, an observation consistent
with epigenetic alterations caused by
R-2-HG, which presumably alters both
DNA and histone methylation. Interest-
ingly, the oncogenic effects of R-2-HG
on TF-1 cells are reversible. If IDH1/2-
mutated tumors were similarly dependent
on the continuous presence of R-2-HG,
inhibition of mutant IDH1/2 could be an
effective therapeutic treatment for these
cancers.
To uncover which a-KG-dependent
dioxygenase serves as the key target of
R-2-HG in transformation, Losman et al.
(2013) performed a small hairpin RNA
knockdown screen of dioxygenase family
members. Their data point to TET2 was
likely a key a-KG-dependent dioxygenase
responsible for the oncogenic function of
R-2-HG among those tested.
There are two enantiomers of 2-HG:
R-2-HG and S-2-HG. Only R-2-HG is
produced by mutant IDH1/2. Both enan-
tiomers inhibit many a-KG-dependent
dioxygenases, with R-2-HG being signifi-
cantly less potent than S-2-HG (Chowd-
hury et al., 2011; Xu et al., 2011; Koivunenet al., 2012). Surprisingly, Losman et al.
(2013) found that R-2-HG, but not S-2-
HG, promoted leukemic transformation
in a dose- and passage-dependent
manner. How then could S-2-HG, being
a more potent inhibitor of TET2, be
ineffective in promoting oncogenic trans-
formation? Koivunen et al. (2012) had
previously reported that S-2-HG inhibits
EglN1, a member of the a-KG-dependent
dioxygenases responsible for HIF-1a
hydroxylation and degradation, whereas
R-2-HG actually promotes EglN1 activity.
The authors showed that inhibition of
EglN1 by S-2-HG might suppress its
ability to promote cytokine-independent
growth and inhibit EPO-induced differen-
tiation. This conclusion is surprising given
the fact that HIF-1a is normally associated
with tumor promotion rather than inhibi-
tion. The data by Losman et al. (2013)
imply that inhibition of EglN1, and hence
accumulation of HIF-1a, may be incom-
patible for leukemogeneis caused by
TET2 inhibition by R-2-HG (Figure 1).
The function of R-2-HG in blocking
differentiation is consistentwithaprevious
report that supports the role of mutantCancer Cell 2IDH1 in suppressing hematopoietic differ-
entiation (Figueroa et al., 2010). Besides
altered DNA methylation, increased his-
tone methylation has also been associ-
ated with the expression of cancer-asso-
ciated mutant IDH1. Therefore, inhibition
of the JmjC family of histone demethy-
lases likely also contributes to tumorigen-
esis. A unified model for tumorigenesis
caused bymutation inmetabolic enzymes
is that inhibition of a-KG-dependent
dioxygenases leads to epigenetic alter-
ations in both DNA and histone, therefore
altering gene expression and oncogenic
transformation (Figure 1). Consistent
with this model, both KDM and TET
enzymes are inhibited by succinate and
fumarate, two metabolites that are
structurally similar to a-KG and are accu-
mulated in cells expressing cancer-asso-
ciated mutant SDH and FH, respectively
(Xiao et al., 2012). Further support for
theepigeneticmodel comes fromamouse
IDH1R132H knockin study that reveals an
increase of both DNA methylation and
histone methylation (Sasaki et al., 2012).
More studies are needed to demonstrate
the functional significance of epigenetic3, March 18, 2013 ª2013 Elsevier Inc. 275
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Previewsmodification and expression of specific
genes that are affected by cancer-associ-
atedmetabolic enzymemutations and the
genetic interaction of R-2-HG with other
oncogenes and tumor suppressor genes.
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